Apalutamide: clinical trials recruiting now
18
Recruiting trials
15
Conditions studied
49
US states with sites
26
Countries
FDA drug label
- FDA-approved
- Yes. Apalutamide appears in the FDA drug-label database. Marketed as ERLEADA.
FDA-approved use
ERLEADA is indicated for the treatment of patients with Metastatic castration-sensitive prostate cancer (mCSPC) Non-metastatic castration-resistant prostate cancer (nmCRPC) ERLEADA is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer. ( 1 ) non-metastatic castration-resistant prostate cancer. ( 1 )
Phase breakdown
Phase 1 3
Phase 2 9
Phase 3 6
Not applicable 1
Conditions being studied
Recruiting trials involving Apalutamide
- A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
- A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
- AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
- Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
- Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial
- Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
- Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
- PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
- Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
- Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
- Surgical Treatment With or Without Apalutamide in Subjects With High Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy and Staged as Oligometastatic With PSMA-PET
- Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Common questions
Is Apalutamide FDA-approved?
Yes, marketed as ERLEADA.
How many recruiting trials involve Apalutamide?
18 recruiting trials across 15 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.